Fig. 3From: Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registryPercentage of patients with PSA ≤ 4 ng/ml over time for (a) all patients; b patients with metastatic disease at baseline; and (c) patients with baseline PSA ≥20 ng/mlBack to article page